Cargando…
NR2F1-AS1 Acts as an Oncogene in Breast Cancer by Competitively Binding with miR-641
BACKGROUND: Long noncoding RNA (lncRNA) NR2F1-AS1 has been previously reported to be dysregulated in human cancers and implicated in the tumorigenesis and development of tumors. In this research, we detected the expression level and biological function of NR2F1-AS1 in breast cancer (BC). METHODS: Th...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786478/ https://www.ncbi.nlm.nih.gov/pubmed/35083026 http://dx.doi.org/10.1155/2022/6778199 |
_version_ | 1784639118849867776 |
---|---|
author | Zhong, Yan Zeng, Weiwei |
author_facet | Zhong, Yan Zeng, Weiwei |
author_sort | Zhong, Yan |
collection | PubMed |
description | BACKGROUND: Long noncoding RNA (lncRNA) NR2F1-AS1 has been previously reported to be dysregulated in human cancers and implicated in the tumorigenesis and development of tumors. In this research, we detected the expression level and biological function of NR2F1-AS1 in breast cancer (BC). METHODS: The expression of NR2F1-AS1 in BC tissues and cell lines was determined by qRT-PCR analysis. The associations of NR2F1-AS1 expression with clinical characteristics and survival rate of BC patients were also analyzed. Cell proliferation, migration, and invasion were measured by the CCK-8 and Transwell assay. RESULTS: The results revealed that the total survival time of BC patients with high NR2F1-AS1 expression was lower than that of BC patients with low NR2F1-AS1 expression. Moreover, functional experiments demonstrated that knockdown of NR2F1-AS1 inhibited BC cell viability, migration, and invasion abilities, whereas overexpression of NR2F1-AS1 had the opposite effect. Mechanistic investigation revealed that NR2F1-AS1 can competitively bind with microRNA-641 (miR-641) in BC. These results revealed that NR2F1-AS1 functioned as an oncogene by sponging miR-641 expression in BC cell progression. Moreover, miR-641 was negatively correlated with NR2F1-AS1 in BC tissues. CONCLUSION: Hence, NR2F1-AS1 was found to act as an oncogene in breast cancer by suppressing miR-641. We suggested that NR2F1-AS1 could be a potential biomarker for BC diagnosis and therapy. |
format | Online Article Text |
id | pubmed-8786478 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-87864782022-01-25 NR2F1-AS1 Acts as an Oncogene in Breast Cancer by Competitively Binding with miR-641 Zhong, Yan Zeng, Weiwei J Healthc Eng Research Article BACKGROUND: Long noncoding RNA (lncRNA) NR2F1-AS1 has been previously reported to be dysregulated in human cancers and implicated in the tumorigenesis and development of tumors. In this research, we detected the expression level and biological function of NR2F1-AS1 in breast cancer (BC). METHODS: The expression of NR2F1-AS1 in BC tissues and cell lines was determined by qRT-PCR analysis. The associations of NR2F1-AS1 expression with clinical characteristics and survival rate of BC patients were also analyzed. Cell proliferation, migration, and invasion were measured by the CCK-8 and Transwell assay. RESULTS: The results revealed that the total survival time of BC patients with high NR2F1-AS1 expression was lower than that of BC patients with low NR2F1-AS1 expression. Moreover, functional experiments demonstrated that knockdown of NR2F1-AS1 inhibited BC cell viability, migration, and invasion abilities, whereas overexpression of NR2F1-AS1 had the opposite effect. Mechanistic investigation revealed that NR2F1-AS1 can competitively bind with microRNA-641 (miR-641) in BC. These results revealed that NR2F1-AS1 functioned as an oncogene by sponging miR-641 expression in BC cell progression. Moreover, miR-641 was negatively correlated with NR2F1-AS1 in BC tissues. CONCLUSION: Hence, NR2F1-AS1 was found to act as an oncogene in breast cancer by suppressing miR-641. We suggested that NR2F1-AS1 could be a potential biomarker for BC diagnosis and therapy. Hindawi 2022-01-17 /pmc/articles/PMC8786478/ /pubmed/35083026 http://dx.doi.org/10.1155/2022/6778199 Text en Copyright © 2022 Yan Zhong and Weiwei Zeng. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Zhong, Yan Zeng, Weiwei NR2F1-AS1 Acts as an Oncogene in Breast Cancer by Competitively Binding with miR-641 |
title | NR2F1-AS1 Acts as an Oncogene in Breast Cancer by Competitively Binding with miR-641 |
title_full | NR2F1-AS1 Acts as an Oncogene in Breast Cancer by Competitively Binding with miR-641 |
title_fullStr | NR2F1-AS1 Acts as an Oncogene in Breast Cancer by Competitively Binding with miR-641 |
title_full_unstemmed | NR2F1-AS1 Acts as an Oncogene in Breast Cancer by Competitively Binding with miR-641 |
title_short | NR2F1-AS1 Acts as an Oncogene in Breast Cancer by Competitively Binding with miR-641 |
title_sort | nr2f1-as1 acts as an oncogene in breast cancer by competitively binding with mir-641 |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786478/ https://www.ncbi.nlm.nih.gov/pubmed/35083026 http://dx.doi.org/10.1155/2022/6778199 |
work_keys_str_mv | AT zhongyan nr2f1as1actsasanoncogeneinbreastcancerbycompetitivelybindingwithmir641 AT zengweiwei nr2f1as1actsasanoncogeneinbreastcancerbycompetitivelybindingwithmir641 |